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reconstruction algorithms have been implemented using 'The 
Reconstruction ToolKit' (RTK), an open source C++ library 
based on 'The Insight ToolKit' (ITK). 
Results: Data from a patient admitted for lung cancer and 
imaged with the Elekta Synergy cone-beam CT has been 
reconstructed with all four reconstruction methods. The 
figure shows a coronal slice extracted from each of the 
volumes. 
 
Conclusions: With a good motion estimation, MC ROOSTER 
yields results similar to those of MC FDK. However, it can be 
used with an imperfect DVF, and MC ROOSTER 
reconstructions can exhibit a motion different from that of 
the DVF. When the DVF extracted from the planning CT 
cannot be assumed to be correct, yet is supposed to be more 
relevant than a null DVF, MC ROOSTER can take advantage of 
it while still allowing residual motion. 
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Purpose/Objective: Heterogeneous uptake of contrast agent 
during Dynamic Contrast Enhanced – MRI experiments is often 
found in patients with locally advanced cervical cancer. The 
information obtained from the heterogeneous enhancement 
within the tumor is likely to reflect distinct domains of 
different underlying tissue characteristics. The hierarchical 
structure of a set of kinetic models may be based on the 
general 2-Compartment eXchange Model (2CXM). Under 
limiting condition this generic model may be simplified to the 
Tofts model (TM) (weakly vascularized), the Extended Tofts 
model (ETM) (highly perfused) and the Compartmental 
Tissue-Uptake model (C-TU) (uptake regime). The aim of this 
study was to evaluate the ability of a set of nested kinetic 
models to classify sub-volumes within cervix cancer tumor 
tissue. The correlation of model selection to tumor stage was 
investigated. 
Materials and Methods: In brief, 15 cervical cancer patients 
with advanced stages (FIGO: IIA/IIB/IIIB/IVA – 1/9/4/1) 
underwent DCE-MRI prior to radiotherapy. DCE-MRI was 
performed using a 3T Philips Achieva scanner and a three-
dimensional (3D) saturation recovery spoiled gradient echo 
technique with 20–24 slices having a 5 mm slice thickness, 
TR/TE of 2.9/1.4 ms, Tsat of 25ms, flip angle (FA) of 10°, in-
plane resolution 2.3 mm x 2.3 mm and 2.1 s time resolution. 
The bolus injected was 0.1 mmol/kg Dotarem at 4 ml/s, 
followed by a 50 ml saline flush. A total of 120 dynamic scans 
were obtained of which 18 time-points were scanned before 
the bolus arrived at the iliac arteries. A T1 relaxation map 
was constructed before contrast injection. The nested set of 
kinetic models included 2CXM, C-TU, ETM and TM. The model 
which described best the temporal contrast agent 
concentration profile (i.e. best fit) was identified using the 
corrected Akaike Information Criteria. For the kinetic 
analysis a population based input function using a similar 
injection profile was applied. For statistical inference a one 
sided non-parametric Wilcoxon rank-sum test was employed 
with the significance level of p<0.05. 
Results: 
 
The main observation was the ability of the hierarchical 
tracer kinetic model sub-volume classification to detect 
distinct contiguous regions within the tumor. The division of 
the tumors into the nested set of kinetic model, measured by 
median and interquartile range (IQR) of volume fraction 
were; TM: 23.4% (12.4% - 32.4%), ETM: 7. 4% (4.6% - 16.4%), 
C-TU: 27.9% (17.6% - 37.9%) and 2CXM: 40.5% (24.6% 43.0%). 
There was a significant difference (p=0.01) in the percentage 
volume best described by TM between patients with tumor 
stage ≤IIB (10 pts) and tumor stage ≥IIIB (5 pts) (Fig. 1.). The 
volume fractions described by the remaining models were not 
found to differ significantly between the stage groups. 
Conclusions: Firstly, we found that the hierarchical kinetic 
classification approach was able to identify contiguous 
regions within tumor tissue in patients with locally advanced 
cervical cancer. Secondly, it was seen that patients with the 
most advanced stages (≥IIIB) tended to be overly expressing 
regions of TM DCE-MRI enhancement profiles.  
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Purpose/Objective: The use of diffusion MRI as a biomarker 
of response to therapy has been investigated in several 
preclinical and clinical studies. Recently the kurtosis model 
(see eq (1)) has been introduced to better characterize the 
DWI signal. The aim of this work is to measure the change of 
Diffusion (D) and Diffusional Kurtosis (k) in the healthy 
prostate tissue and in the tumour after radiation therapy. 
Materials and Methods: Ten patients with biopsy-proven 
prostate cancer, underwent diffusion weighted MRI (1.5 T) at 
b values (0, 500, 1000, 1500 s/mm2) before and after 
radiation therapy with curative intent (table1).  
A total of 31 lesions were identified at pre treatment MRI. 
Median time between end of therapy and MRI scan was 100 
days (max 221, min 77). 
Change in Diffusion and Diffusional Kurtosis (D, k) were 
estimated in the healthy prostate gland and in the cancer, 
through the relation (1): 
(1) ln[S(b)]=ln[S(0)]-bD+1/6D2b2k 
Change in the serum-specific antigen (PSA) levels was 
additional evaluated. 
 
 
Results: Results are shown in fig1. The mean Diffusion value 
(1767 µ mm2/s) increases significantly (p<0.001) in tumour 
after therapy (pre treatment value 1295 µ mm2/s) and 
decreases in the healthy tissue (1838 µ mm2/s post 
treatment vs 2097 µ mm2/s pre treatment, p<0.05). 
Diffusional Kurtosis decreases significantly (p<0.01) in the 
tumour (1.3 vs 1.01) and shown not significant variation after 
therapy in the healthy prostate tissue (0.92 post-treatment vs 
0.86 pre-treatment). 
 
Conclusions: The measure of the diffusion properties of 
water in prostate carcinoma and in the healthy prostate 
tissue, before and after curative radiation therapy, is able to 
characterize the response to the irradiation. This study 
indicated that Diffusional Kurtosis is a promising biomarker 
for evaluation of tumour response to radiation therapy and 
can be used for follow-up.   
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Major progress in modern oncological treatment over the last 
decades has turned cancer increasingly into a more chronic 
and less life threatening disease and has led to an increasing 
number of cancer survivors. Therefore, in addition to 
classical clinical endpoints in cancer studies like survival, 
disease control rates and physician assessed morbidity, 
health-related quality of life and patient reported outcomes 
have considerably gained importance, as many patients have 
to face potential impairments for a long time.  
Furthermore, the increasing use of highly effective combined 
treatments raises concerns about the impact of morbidity on 
patients' quality of life. Health-related quality of life 
describes ‘the patient’s subjective perception of the impact 
of his disease and its treatment(s) on his/her daily life, 
physical, psychological and social functioning and well-
being’, according to the European Medicines Agency [EMA 
2005]. 
Traditional morbidity grading systems, especially the most 
frequently used Common Terminology Criteria of Adverse 
Events (CTCAE) of the US National Cancer Institute, involve 
an assessment by physicians with a comprehensive translation 
of patients’ narrative statements into medical terms and 
grades, with or without interpretation of their impact on 
activities of daily life, decisions about medical interventions, 
analytic (test) results and objective findings of examination 
[Trotti et al. 2007]. CTCAE morbidity endpoints offer 
therefore a wide range of clinical interpretation and have 
shown only a moderate inter-observer reliability [Atkinson et 
al. 2012].  
In comparison, patient reported outcomes represent a 
subjective evaluation in terms of quantifying frequency 
and/or intensity of symptoms and/or their impact on 
activities of daily life. They are assessed directly from the 
patient, mainly with questionnaires and without any clinical 
interpretation [Basch et al. 2012]. Therefore, they provide 
the most direct feedback reflecting the patients’ experience 
with disease and treatment and are increasingly recognized 
as reliable and valid endpoints in clinical studies. 
Several reports in literature indicate substantial variations 
between physician assessed morbidity and patient reported 
symptoms, mainly suggesting underreporting of milder to 
moderate symptoms in physician assessed morbidity [Fromme 
et al. 2004, Vistad et al. 2008, Davidson et al. 2007, Velikova 
et al. 2001, Kirchheiner et al. 2012]. 
From a methodological point of view, comparisons are 
restricted, as the physician assessed grading system and the 
answer categories of patient reported symptoms in a 
questionnaire do not follow a linear association. 
Nevertheless, it has been shown that discrepancies are 
frequently observed, if the patient reports substantial 
symptoms, which are not recognized by the physician in the 
